Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers



Status:
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:8/15/2012
Start Date:June 2010
End Date:January 2013

Use our guide to learn which trials are right for you!

Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy


The purpose of this Phase 3 study is to evaluate overall survival and progression free
survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in
combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients
with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.


Squamous cell carcinoma of the head and neck is the sixth most common cancer in the world.
More than 50% of patients diagnosed with advanced regional disease will relapse locally or
at distant sites. Initial therapeutic options include irradiation, surgery and chemotherapy.
The most commonly used agents are cisplatin and carboplatin, generally in combination with
5-FU or a taxane. Erbitux has been approved for use in first-line with radiation and in
second-line as monotherapy. Only about a third of the patients will respond to first-line
platinum-based therapy and the median overall survival is about 6-9 months.

Preliminary assessment of a Phase 1-2 study conducted in the UK investigating the
combination of REOLYSIN, carboplatin and paclitaxel suggested that patients with head and
neck carcinomas may represent a group of patients in whom this treatment combination is
active. Studies have also shown that paclitaxel and carboplatin combination therapy may be
effective in head and neck cancers, even in heavily pretreated patients and those resistant
to previous treatment. These results strongly support the utility of the
carboplatin/paclitaxel combination as a control arm for salvage therapy in platinum
refractory patients, a patient group with few and poor treatment options and with no gold
standard therapy.

This Phase 3 study is designed to compare response rates following intravenous
administration of REOLYSIN (Reovirus Type 3 Dearing) in combination with paclitaxel and
carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent
Squamous Cell Carcinoma of the Head and Neck.

Overall survival is a primary endpoint of this trial. Patients will be clinically evaluated
after each course of treatment and radiologically every 6 weeks on and after treatment. The
safety of the paclitaxel and carboplatin with intravenous blinded placebo or intravenous
blinded REOLYSIN will also be assessed.

Inclusion Criteria: Each patient MUST:

- have recurrent or metastatic (R/M) histologically confirmed squamous cell carcinoma
(SCC) of the head and neck (oropharynx, oral cavity, larynx, hypopharynx) or squamous
cell nasopharynx cancer (NPC) with distal metastasis(es) and no secondary cancers
(Patients with NPC without distal metastasis(es) or with undifferentiated NPC are not
eligible).

- have at least one lesion that is measurable by computed tomography or magnetic
resonance imaging (Lesions persisting in previously treated radiation fields are
considered not evaluable for response except if representing a relapse in a mucosal
or nodal lesion that previously demonstrated a complete response. Any new lesion
within the previous radiation fields is acceptable for determination of response
and/or progression).

- have completed first line chemotherapy for R/M SCCHN which progressed on or within
190 days following the completion of platinum or platinum-based chemotherapy.

- have no continuing acute toxic effects (except alopecia) of any prior radiotherapy,
chemotherapy, or surgical procedures. Any surgery involving the SCC for which the
patient is being treated (except biopsies) must have occurred at least 28 days prior
to study enrollment.

- have received no chemotherapy, radiotherapy, immunotherapy or hormonal therapy within
28 days.

- have ECOG Performance Score of ≤ 2.

- have life expectancy of at least 3 months.

- absolute neutrophil count (ANC)≥ 1.5 x 10^9/L ; platelets ≥100 x 10^9/L]; hemoglobin
≥9.0 g/dL; serum creatinine ≤1.5 xULN; bilirubin ≤1.5 x ULN; AST/ALT ≤2.5 x ULN.

- negative pregnancy test for females with childbearing potential.

- Be wiling and able to comply with scheduled visits, the treatment plan, and
laboratory tests.

Exclusion Criteria: No patient may:

- receive concurrent therapy with any other investigational anticancer agent while on
study.

- have been treated with a taxane for SCCHN.

- have current -- or with a history of -- brain metastases because of their poor
prognosis and because of the frequent development of progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse
events.

- be on chronic immunosuppressive therapy or have known HIV infection or active
hepatitis B or C.

- be a pregnant or breast-feeding woman. Female patients of childbearing potential
must agree to use effective contraception, be surgically sterile, or be
postmenopausal. Male patients must agree to use effective contraception or be
surgically sterile. Barrier methods are a recommended form of contraception.

- have clinically significant cardiac disease (New York Heart Association, Class III or
IV) including, but not limited to, pre-existing arrhythmia, uncontrolled angina
pectoris, or myocardial infarction within 1 year prior to study entry.

- have dementia or any altered mental status that would prohibit informed consent.

- have any other acute, or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration or may interfere with the interpretation of study results and, in
the judgment of the Principal Investigator, would make the patient inappropriate for
this study.
We found this trial at
25
sites
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1 Gustave L Levy Pl # 504
New York, New York 10029
 (212) 241-6500
Mount Sinai School of Medicine Icahn School of Medicine at Mount Sinai is proud to...
?
mi
from
New York, NY
Click here to add this to my saved trials
3040 W Salt Creek Lane
Palatine, Illinois 60005
(847) 394-6455
?
mi
from
Palatine, IL
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Burbank, California 91505
?
mi
from
Burbank, CA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80218
?
mi
from
Denver, CO
Click here to add this to my saved trials
Elyria, Ohio 44035
?
mi
from
Elyria, OH
Click here to add this to my saved trials
7360 W. Deschutes
Kennewick, Washington 99336
509-783-0144
Columbia Basin Hematology and Oncology Our collaboration with Seattle Cancer Care Alliance gives you convenient...
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
La Verne, California 91750
?
mi
from
La Verne, CA
Click here to add this to my saved trials
9280 W. Sunset Road Suite 100
Las Vegas, Nevada 89148
702.952.1251
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
New Port Richey, Florida 34642
?
mi
from
New Port Richey, FL
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
Richmond, Virginia 23298
?
mi
from
Richmond, VA
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Tucson, Arizona 85745
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tyler, Texas 75702
?
mi
from
Tyler, TX
Click here to add this to my saved trials